MX2007001029A - Agentes del receptor de histamina h3, preparacion y usos terapeuticos. - Google Patents

Agentes del receptor de histamina h3, preparacion y usos terapeuticos.

Info

Publication number
MX2007001029A
MX2007001029A MX2007001029A MX2007001029A MX2007001029A MX 2007001029 A MX2007001029 A MX 2007001029A MX 2007001029 A MX2007001029 A MX 2007001029A MX 2007001029 A MX2007001029 A MX 2007001029A MX 2007001029 A MX2007001029 A MX 2007001029A
Authority
MX
Mexico
Prior art keywords
methyl
ethyl
pyrrolidin
oxazol
phenyl
Prior art date
Application number
MX2007001029A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Selsam Beavers
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Serge Louis Boulet
Grant Matthews Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2007001029A publication Critical patent/MX2007001029A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2007001029A 2004-07-26 2005-07-14 Agentes del receptor de histamina h3, preparacion y usos terapeuticos. MX2007001029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
MX2007001029A true MX2007001029A (es) 2007-04-12

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007001029A MX2007001029A (es) 2004-07-26 2005-07-14 Agentes del receptor de histamina h3, preparacion y usos terapeuticos.

Country Status (17)

Country Link
US (1) US7666871B2 (enExample)
EP (1) EP1786790B1 (enExample)
JP (1) JP4982367B2 (enExample)
CN (1) CN1989115B (enExample)
AT (1) ATE432926T1 (enExample)
AU (1) AU2005275183B2 (enExample)
BR (1) BRPI0513777A (enExample)
CA (1) CA2575081C (enExample)
CY (1) CY1109493T1 (enExample)
DE (1) DE602005014786D1 (enExample)
DK (1) DK1786790T3 (enExample)
ES (1) ES2325865T3 (enExample)
MX (1) MX2007001029A (enExample)
PL (1) PL1786790T3 (enExample)
PT (1) PT1786790E (enExample)
SI (1) SI1786790T1 (enExample)
WO (1) WO2006019833A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1848428A4 (en) 2005-02-18 2012-04-18 Neurogen Corp THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS
US7790720B2 (en) 2005-03-31 2010-09-07 Ucb Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
AU2006316079B2 (en) 2005-11-15 2012-03-29 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2009530274A (ja) 2006-03-15 2009-08-27 ワイス ヒスタミン−3アンタゴニストとしてのn−置換−アザシクリルアミン化合物
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
EP2024327A1 (de) * 2006-05-19 2009-02-18 Basf Se Benzoylsubstituierte alanine
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR067549A1 (es) * 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
ES2909086T3 (es) 2017-01-11 2022-05-05 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
SG11202000970WA (en) 2017-08-07 2020-02-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
AU674613B2 (en) * 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
BR0306980A (pt) 2002-02-01 2004-11-09 Novo Nordisk As Composto, uso de um composto, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com o receptor de histamina h3
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
JP2008507579A (ja) 2008-03-13
ES2325865T3 (es) 2009-09-22
CN1989115A (zh) 2007-06-27
AU2005275183B2 (en) 2011-03-17
JP4982367B2 (ja) 2012-07-25
EP1786790B1 (en) 2009-06-03
CN1989115B (zh) 2012-03-21
DE602005014786D1 (de) 2009-07-16
BRPI0513777A (pt) 2008-05-13
DK1786790T3 (da) 2009-07-20
ATE432926T1 (de) 2009-06-15
SI1786790T1 (sl) 2009-10-31
PT1786790E (pt) 2009-08-18
CA2575081A1 (en) 2006-02-23
EP1786790A1 (en) 2007-05-23
AU2005275183A1 (en) 2006-02-23
CY1109493T1 (el) 2014-08-13
US7666871B2 (en) 2010-02-23
WO2006019833A1 (en) 2006-02-23
CA2575081C (en) 2013-05-07
PL1786790T3 (pl) 2009-10-30
US20070197604A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
CA2575081C (en) Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
JP4942654B2 (ja) ヒスタミンh3受容体薬剤、製剤及び治療的使用
US11084784B2 (en) ROR-gamma modulators and uses thereof
CN101528717B (zh) 噻唑和*唑-取代的芳基酰胺类化合物
US6610696B2 (en) Modulators of peroxisome proliferator activated receptors
US7528160B2 (en) Fused heterocyclic derivatives as PPAR modulators
AU5731099A (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
WO2007126043A1 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
JP5318883B2 (ja) トリアゾ−ル置換アリールアミド誘導体およびp2x3および/またはp2x2/3プリン受容体アンタゴニストとしてのそれらの使用
AU2006228690A1 (en) Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
TW200526588A (en) Chemical compounds
CZ2004272A3 (cs) Perorální antidiabetická činidla
WO2011145735A1 (ja) チアゾール誘導体
KR20030027054A (ko) 옥사졸릴-아릴프로피온산 유도체 및 ppar효능제로서의 그의 용도
MX2015002624A (es) Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5.
WO2006049232A1 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
KR20120047960A (ko) 글루코키나아제(gk) 활성화제로서 치환된 벤즈아미드 유도체
CN1980906A (zh) 作为ppar调节剂的化合物和组合物
HK1170232A (en) Substituted benzamide derivatives as glucokinase (gk) activators

Legal Events

Date Code Title Description
FG Grant or registration